Items Tagged ‘ENDEAVOR’

January 26th, 2016

Combo Therapy of Kyprolis plus Dexamethasone Approved for Recurrent Multiple Myeloma

By

The United States Food and Drug Administration (FDA) recently approved a new treatment combination consisting of Kyprolis (carfilzomib) plus dexamethasone for patients with relapsed or refractory multiple myeloma. Multiple myeloma is a type of blood cancer that affects certain immune cells called plasma cells. Healthy plasma cells produce proteins called antibodies that are an important […]

View full entry

Tags: carfilzomib, dexamethasone, ENDEAVOR, fda, kyprolis, Multiple Myeloma, News, Recurrent Multiple Myeloma


April 27th, 2015

Study Demonstrates Superiority Of Kyprolis® over Velcade® in Patients With Relapsed Multiple Myeloma

By

The results from a planned interim analysis of the Phase 3 head-to-head clinical trial ENDEAVOR evaluating Kyprolis® (carfilzomib in combination with low-dose dexamethasone versus Velcade® (bortezomib) and low-dose dexamethasone have demonstrated that the Kyprolis® treated patients lived twice as long without their disease worsening. Multiple myeloma is a cancer of plasma cells, which are a […]

View full entry

Tags: bortezimib, carfilzomib, ENDEAVOR, kyprolis, Multiple Myeloma, News, velcade